论文部分内容阅读
目的:探讨左卡尼汀与蔗糖铁注射液应用于维持性血液透析(MHD)患者肾性贫血中的可行性。方法:选取我院2012年11月-2015年2月接收的MHD出现肾性贫血的患者120例,采用数字表法将其分为对照组与研究组,对照组患者给予蔗糖铁注射液治疗,研究组在对照组基础上应用左卡尼汀治疗,对比两组患者Hb、HCT、SF、TSAT各指标水平及临床疗效。结果:研究组与对照组患者Hb、HCT、SF、TSAT各指标水平相比差异显著(P<0.05);研究组患者总有效率93.33%明显高于对照组76.67%差异明显(P<0.05)。结论:MHD患者肾性贫血中应用左卡尼汀与蔗糖铁注射液联合治疗的效果较好,可推广应用。
Objective: To investigate the feasibility of using levocarnitine and sucrose iron injection in renal anemia patients with maintenance hemodialysis (MHD). Methods: One hundred and twenty patients with renal anemia who received MHD from November 2012 to February 2015 in our hospital were selected and divided into control group and study group by digital meter method. Patients in control group were treated with sucrose iron injection, The study group in the control group based on the application of levocarnitine treatment, the two groups were compared Hb, HCT, SF, TSAT indicators and clinical efficacy. Results: The difference of Hb, HCT, SF and TSAT between study group and control group was significant (P <0.05). The total effective rate was 93.33% in study group and 76.67% in control group (P <0.05) . Conclusion: The combination therapy of levocarnitine and sucrose iron injection in renal anemia patients with MHD is better and can be widely used.